Clinical investigation on target value of T>MIC in carbapenems

Japanese Journal of Antibiotics

Volumn 61, Issue 2, 2008, Pages 73-81

  Mikamo, Hiroshige ^a,b   Yamagishi, Yuka ^a   Tanaka, Kaori ^b   Watanabe, Kunitomo ^b  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIAPENEM; CARBAPENEM DERIVATIVE; MEROPENEM; THIENAMYCIN DERIVATIVE;

ABSCESS; AEROBIC BACTERIUM; ANAEROBIC INFECTION; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONCENTRATION RESPONSE; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PELVIC INFLAMMATORY DISEASE; ADULT; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; DRUG ADMINISTRATION; DRUG EFFECT; ESCHERICHIA COLI; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; STAPHYLOCOCCUS AUREUS;

ADULT; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; CARBAPENEMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; FEMALE; HUMANS; MIDDLE AGED; PELVIC INFLAMMATORY DISEASE; STAPHYLOCOCCUS AUREUS; THIENAMYCINS;

EID: 51449109157     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Jpn. J. Antibiotics 55: 875-881, 2002
2. Japanese source
3. Jpn. J. Antibiotics 59: 459-467, 2006
4. Jpn. J. Antibiotics 58: 452-457, 2005
5. Jpn. J. Antibiotics 60: 459-467, 2006
6. Japanese source
7. Japanese source
8. VINCENT, H. T.; N. S. AMY, A. C. ELIZABETH, et al.: Optimizing of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 4920-4927, 2005
9. Japanese source
10. Jpn. J. Antibiotics 60: 47-57, 2007
11. CRAIG, W. A.: Interrelationship between pharmacokinetic and pharmacodynamic in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22: 89-96, 1995
12. CRAIG, W. A.: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosings of mice and men. Clin. Infect. Dis. 26: 1-12, 1998
13. CRAIG, W. A.: The role of pharmacodynamics in effective treatment of community-acquired pathogens. Advanced Stud. Med. 2: 126-134, 2002
14. DRUSANO, G. L.: Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36 (Suppl. 1): S42-S50, 2003
15. Chemotherapy 40 (S-1): 258-275, 1992
16. Chemotherapy 42 (S-4): 277-284, 1994
17. CHONGHUA, L. X.; J. L. KUTI & D. P. NICOLAU: Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob. Agents Chemother. 51: 1725-1730, 2007
18. TAKATA, T.; K. AIZAWA, K. TOTSUKA, et al.: Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J. Infect. Chemother. 10: 76-85, 2004
19. LODISE, T. P.; R. NAU, M. KINZIG, et al.: Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluide: results of population pharmacokinetics modeling and Monte Carlo Simulation. J. Antimicr. Chemoth. 60: 1038-1044, 2007
20. Japanese source
21. Japanese source
22. Jpn. J. Antibiotics 51: 532-534, 1998
23. Japanese source